Cellzome Announces Exercise of Option to Alzheimer's Compounds

May 23, 2005

Cellzome announced that Ortho-McNeil Pharmaceutical has exercised its option to license and develop Cellzome's Gamma Secretase Modulator (GSM) program, under the terms of their March 2005 collaboration agreement. The program includes identifying new medicines for the treatment of Alzheimer's disease. Under the terms of the collaboration, Cellzome will receive an additional technology access fee and continued research funding to deliver clinical drug candidates to Ortho-McNeil Pharmaceutical.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20156120&full=1)